Tirzepatide dosing for weight loss: what the schedule actually looks like

What NICE and the trial data say about the dosing schedule

The licensed Mounjaro dosing schedule for weight loss was the backbone of the SURMOUNT-1 trial, which ran for 72 weeks and enrolled 2,539 adults with obesity. Participants titrated through the same 4-week steps that appear on the UK SmPC, reaching 10 mg, 12.5 mg or 15 mg as their assigned maintenance dose. At 15 mg, average body-weight reduction was around 20–21%, a result that NICE cited directly when it recommended tirzepatide for weight management in December 2024. You can read NICE's full recommendation at NICE technology appraisal TA1026.

The titration structure isn't arbitrary. Starting at 2.5 mg allows the gastrointestinal system to adapt before the dose climbs; nausea and other GI effects are most pronounced at the beginning or after a step-up, and holding at each rung for four weeks meaningfully reduces how many people stop treatment early. The NHS patient information for tirzepatide sets out this same principle, you can read it at NHS.UK's tirzepatide medicines page. What the trial also showed is that the 10 mg and 12.5 mg doses produced substantial results in their own right; not everyone needs or tolerates 15 mg, and a prescriber's job is finding the highest dose that works well for you individually.

For practical context on how the medication itself arrives once approved: it comes as a pre-filled KwikPen, each pen containing four weekly doses, delivered by tracked, plain-packaged courier the next working day after dispatch, DPD sends a tracking link to your phone so you know exactly when to expect it.

Tirzepatide dosing in ml: why this question keeps coming up

A number of people search for tirzepatide dosing for weight loss in ml, usually because they've seen the KwikPen and noticed it's pre-filled with a liquid. The short answer is that you don't need to think in millilitres. The KwikPen is a fixed-dose device: you dial to the prescribed dose in milligrams, press and hold, and the pen delivers the correct volume automatically. There is no syringe to fill, no calculation to make, and no way to accidentally draw up the wrong amount.

This is genuinely different from older injection systems. The pen's mechanism handles the conversion, so the relevant unit is always milligrams, 2.5 mg, 5 mg, and so on up the ladder. If you are switching from a different injectable weight-loss treatment, or you're reading older information written for vial-and-syringe formats, that's usually where the ml question comes from. The patient information leaflet packaged with your pen covers injection technique in full; your prescriber or our aftercare team can also walk you through it. More detail on the full tirzepatide dosing guide is available if you want to go deeper before your consultation.

One point worth flagging: if you ever see tirzepatide described by volume online (particularly from unverified sellers) treat that as a warning sign. Legitimate UK supply comes in labelled, pre-filled pens through a regulated pharmacy, not loose vials requiring home measurement.

Who the dosing schedule applies to, and when it needs adjusting

The licensed schedule applies to adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition such as high blood pressure, raised cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone doesn't determine whether tirzepatide is appropriate, that's the prescriber's assessment, which takes in your full health picture, any existing conditions, and medications you're already taking.

Certain situations genuinely change how dosing plays out. If side effects are significant at 5 mg, a prescriber may hold you there for eight weeks rather than four before moving up. If you reach 10 mg and weight loss is progressing well with no troublesome effects, they may still titrate further, the goal is the highest dose that keeps you comfortable and effective. NICE's recommendation notes that if less than 5% weight loss has occurred after six months at the highest tolerated dose, continuing should be reviewed. That's a clinical conversation, not a rule you apply to yourself.

People considering a switch from another treatment, or those asking about tirzepatide's weight-loss results more broadly, often wonder whether dose changes between products are straightforward. They're not; there's no direct conversion. A prescriber reviews evidence of your current dose and progress before making any recommendation. Our clinical team handles exactly these conversations every week.

What the dosing schedule doesn't cover, and where to get proper guidance

The schedule described here is factual information about how tirzepatide is used in licensed UK practice. It doesn't tell you what dose you should be on, when to increase, or what to do if you miss a dose, those questions belong to your prescriber and the patient information leaflet that arrives with your treatment. The same applies to stopping: coming off tirzepatide abruptly or changing dose without clinical input carries real risks, and the right route is a conversation, not a self-directed adjustment.

If you're weighing up whether tirzepatide is the right approach for you at all, the Mounjaro overview covers the broader picture, and our tirzepatide information page goes into mechanism and eligibility in more detail. There's also an honest look at the drawbacks of Mounjaro for anyone who wants the less-discussed side of the conversation. If cost is a factor in your thinking, the context behind recent UK price changes is worth reading before you compare providers.

When you're ready to find out whether you're clinically suitable, our prescribers review every application the same day it's submitted, a real clinician, not automated scoring. Check your eligibility with a free consultation and get a clear answer quickly.